Top

Intensive Care Medicine

Published in:

01-02-2021 | Correspondence

Midodrine administration during critical illness: fixed-dose or titrate to response?

Authors: Richard R. Riker, David J. Gagnon

Published in: Intensive Care Medicine | Issue 2/2021

Excerpt

Dear Editor, …

Santer P, Anstey MH, Patrocínio MD, Wibrow B, Teja B, Shay D, Shaefi S, Parsons CS, Houle TT, Eikermann M, MIDAS Study Group (2020) Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. Intensive Care Med. https://doi.org/10.1007/s00134-020-06216-xCrossRefPubMed

Levine AR, Meyer MJ, Bittner EA, Berg S, Kalman R, Stanislaus AB, Ryan C, Ball SA, Eikermann M (2013) Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care 28(5):756–762. https://doi.org/10.1016/j.jcrc.2013.05.021CrossRefPubMed

Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, Mayo PH (2016) Feasibility, utility, and safety of midodrine during recovery phase from septic shock. Chest 149(6):1380–1383. https://doi.org/10.1016/j.chest.2016.02.657CrossRefPubMed

Poveromo LB, Michalets EL, Sutherland SE (2016) Midodrine for the weaning of vasopressor infusions. J Clin Pharm Ther 41(3):260–265. https://doi.org/10.1111/jcpt.12375CrossRefPubMed

Rizvi MS, Trivedi V, Nasim F, Lin E, Kashyap R, Andrijasevic N, Gajic O (2018) Trends in use of midodrine in the ICU: a single-center retrospective case series. Crit Care Med 46:e628–e633. https://doi.org/10.1097/CCM.0000000000003121CrossRefPubMed

Tremblay J, Laramée P, Lamarche Y, Denault A, Beaubien-Souligny W, Frenette J, Kontar L, Serri K, Charbonney E (2020) Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study. Ann Intensive Care 10:121. https://doi.org/10.1186/s13613-020-00737-wCrossRefPubMedPubMedCentral

Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA (1998) A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 51(1):120–124. https://doi.org/10.1212/wnl.51.1.120CrossRefPubMed

Rizvi MS, Nei AM, Gajic O, Mata KC, Barreto EF (2019) Continuation of newly initiated midodrine therapy after intensive care and hospital discharge: a single center retrospective study. Crit Care Med 47(8):e648–e653. https://doi.org/10.1097/CCM.0000000000003814CrossRefPubMed

Title: Midodrine administration during critical illness: fixed-dose or titrate to response?
Authors: Richard R. Riker
David J. Gagnon
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 2/2021
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-020-06321-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Midodrine administration during critical illness: fixed-dose or titrate to response?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2021

Artificial intelligence in telemetry: what clinicians should know

Trends in clinical profiles, organ support use and outcomes of patients with cancer requiring unplanned ICU admission: a multicenter cohort study

High-dose midodrine is not effective for treatment of persistent hypotension in the intensive care unit

Critically ill patients with COVID-19: are they hemodynamically unstable and do we know why?

Long term outcomes of critically ill COVID-19 pneumonia patients: early learning

Leaving a mark: pressure injury research in the intensive care unit